Prothena's Late-Stage Study for AL Amyloidosis Fails, Stock Down

Prothena (PRTA) shares fell 22.5% after hours on May 23rd following the announcement that its Phase III AFFIRM-AL study of birtamimab for AL amyloidosis failed to meet its primary endpoint of time to all-cause mortality, leading to the discontinuation of the drug's development and a planned reduction in organizational size; the company's focus now shifts to partnered programs with Roche and Novo Nordisk, with updates expected in mid-2025 and the second half of 2025, respectively, as well as early-stage pipeline programs with Bristol Myers.

Analysis

Prothena Corporation (PRTA) experienced a significant setback with the failure of its late-stage AFFIRM-AL clinical study for birtamimab in AL amyloidosis, leading to a 22.5% decline in its shares in after-hours trading on May 23 and a cumulative year-to-date loss of 52.5%, starkly underperforming the industry's 5% decline. The discontinuation of birtamimab, a wholly-owned, potential best-in-class anti-amyloid antibody, was triggered by the study's inability to meet its primary endpoint of all-cause mortality, as well as its secondary endpoints, despite a generally safe and well-tolerated profile. Consequently, Prothena will cease all development of birtamimab, including its open-label extension, and expects to implement substantial reductions in operating expenses and organizational size, with further details anticipated in June. The company's strategic focus now pivots entirely to its partnered programs and earlier-stage pipeline. Key upcoming catalysts include updates on collaborations with Roche for prasinezumab in Parkinson's disease (where the Phase IIb PADOVA study missed its primary endpoint but showed some positive trends, with Roche to determine next steps by mid-year 2025) and Novo Nordisk for Coramitug in ATTR amyloidosis (Phase II ongoing, updates expected in the second half of 2025). Additionally, early-stage programs with Bristol Myers for Alzheimer's disease (BMS-986446, Phase II completion expected 2027) and other neurodegenerative diseases (PRX019, Phase I completion expected 2026) now carry the weight of future value generation.

Key Decisions for Investors

• Investors should recognize the substantial negative impact of the birtamimab trial failure on Prothena's valuation and the heightened risk profile, as the company is now heavily reliant on its partnered and earlier-stage pipeline assets which have extended development timelines and inherent uncertainties.
• Close attention should be paid to the company's forthcoming June update on restructuring and cost-reduction measures, as these will be critical for financial sustainability and operational realignment.
• Future valuation will be highly sensitive to clinical trial outcomes and milestone updates from partnerships with Roche (mid-2025), Novo Nordisk (H2 2025), and Bristol Myers (2026-2027), requiring patience and a high tolerance for binary event risk associated with biotech drug development.